ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 08 4:00PM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
lovethatgreen lovethatgreen 4 minutes ago
Parallel trials ? Rof dude

It states very clearly in the q human trials will be in se Asia prior to human trials in the usa .

The bedtime stories that are presented here ignoring what has been communicated directly from the company is stunning .

He also s
RDGL
prototype_101 prototype_101 5 minutes ago
TWST: Can you give some idea of how much advantage there is in terms of transmitting information versus using semiconductors?

Dr. Lebby: The incumbent technology today is semiconductors. These are materials like silicon, lithium niobate, or indium phosphide. These are all semiconducto
LWLG TWST
The Danish Dude The Danish Dude 9 minutes ago
And how long does it usually take to prove the efficacy of a glioblastoma treatment with OS endpoint?

SurVaxM started in 2013 and might still need a phase 3 trial.

From ASM this year

So we, we have some collaboration discussions underway, and at the appro
ASM NWBO
Mr. Zen Mr. Zen 10 minutes ago
AAH, Now I know why you did not make money in the market, you don't know how to read a 10-K

Leopard Energy (f/k/a Cyber Apps World Inc.) was incorporated on July 15, 2002, under the laws of the State of Nevada and engaged in a number of businesses until April 9, 2015, at which we merg
LEEN
Mdk1 Mdk1 11 minutes ago
New Paper out by ETH Zürich & Polariton Technologies: “ Plasmonic Modulators for Future High-Capacity Space Communication “
https://www.research-collection.ethz.ch/bitstream/handle/20.500.11850/709178/FiO_2024_PlasmonicsForSpace_sub2.pdf?sequence=1&isAllowed=y
https://www.research-col
LWLG
Maxthedog Maxthedog 15 minutes ago
Next gap on the downside will be .45.
ELTP
Konaploinks Konaploinks 19 minutes ago
IonQ has developed a significant patent portfolio that underscores its leadership in quantum computing technology. As of December 2024, the company holds over 600 issued and pending U.S. and international patents, which focus on innovations that enhance performance, scalability, and enterprise-grade
IONQ
knrorrel knrorrel 21 minutes ago
100 % i agree , the trend is clear to everyone - tomorrow it continues - $GVSI, too $FORW and .......

which favorites are there that will make the OTC hot again starting tomorrow ?
FORW GVSI
SunshineSmiles SunshineSmiles 25 minutes ago
Quite the potential indeed.

Current speed bump is Tynan dumping his 40 million shares at .02.

After that... BOOM!

[yt]-zwYU5Jf2X8?si=Yq-CM_BwNjN1xTMr[/yt]

IndexR
MONI
MONI
prototype_101 prototype_101 34 minutes ago
Lebby set out SAM/SOM guidance at the 2023 ASM, in 2024 coincident with the ONE AND ONLY TIMELINE he has used since at least as far back as the 2019 ASM, the Customer Acceptance was set for 2024 with SAM/SAM guidance for 2024 of 7900 modulators which would have been indicative of SAMPLING, heck that
ASM LWLG
JohnnyJay JohnnyJay 38 minutes ago
Dino,
Very glad to see someone else doing DD. I purchased my first D-wave on June 6th and have been slowly buying since that date. Consider these two components. The NQIA and Davidson Technologies. You can find info on my previous posts. Yes, federal contracts are forth coming. Another huge c
QBTS
TheSprinx TheSprinx 39 minutes ago
Here's a great thread to read.
Explains everything well. 👏🏼
https://x.com/wwtp_consultant/status/1865333541577310409?s=46&t=FWyCU7KfIDokGToTtqinIg

HMBL
TrendTrade2016 TrendTrade2016 40 minutes ago
you are late again...1.20 to 5.00
UPC
Zorch305 Zorch305 44 minutes ago
Good morning....Got RNVA?
RNVA
Nerd Beautiful Nerd Beautiful 44 minutes ago
Our big breakout is 12-18 months away! (And always will be) 🤣
LQMT
Papillionlover Papillionlover 46 minutes ago
Linked in says they are doing a crowdfunding?
ASPZ
manibiotech manibiotech 49 minutes ago
Proven in NWBO world means a decade
NWBO
SHEEPWOLF SHEEPWOLF 54 minutes ago
$ILLR: #Triller
THINK MARKET SHARE.
MARKET SHARE =REVENUE
Creators should be making the move to #Triller and taking advantage of its creator centric tools.
THINK MONETIZATION!
#TikTok

https://www.cnn.com/2024/12/07/tech/tiktok-ban-law-ruling-w
ILLR
mwab52 mwab52 55 minutes ago
Time to wakie,wakie......🤑🤑........Go (RNVA & Team)
RNVA
prototype_101 prototype_101 56 minutes ago
nrdc, only an imbecile could be around here since 2007 and NOT understand what they had invested in so I guess YOU qualify as the chief imbecile here, the Industry had ALREADY been trying and FAILING for 20 years to perfect a Polymer when LWLG just got started in a tiny closet sized lab, and what YO
LWLG
europa7 europa7 57 minutes ago
"Blockchain, AI and Quantum Computing: Exploring the Synergy and Future Opportunities Amid Infrastructure Challenges"
Dec 5, 2024
https://x.com/hedera/status/1864773918260678663

Hedera
@hedera
Upcoming session with Dr. @leemonbaird, Co-Founder of #Hedera an
HBARUSD
mwab52 mwab52 60 minutes ago
Good morning (RNVA-Land & Team)......🤑😎.......Go (RNVA & Team)
RNVA

Your Recent History

Delayed Upgrade Clock